IDT Australia Limited (IDT) AI Stock Analysis

• Market Cap: AU$24.40M
• Dividend Yield: N/A
• Average Volume (3M): 273.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 45.30%
• EPS Growth: -24.18%
• Country: AU
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 429,744,570
• 10 Day Avg. Volume: 190,780
• 30 Day Avg. Volume: 273,334
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by consistent losses and negative cash flows. Technical analysis further supports a bearish outlook, with the stock trading below key moving averages and showing negative momentum indicators. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield, making the stock less attractive to investors.

IDT Australia Limited Business Overview & Revenue Model

Company Description

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.

How the Company Makes Money

IDT Australia Limited generates revenue primarily through the manufacturing and sale of pharmaceutical products. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms, which are sold to pharmaceutical companies, hospitals, and other healthcare providers. Additionally, IDT offers contract manufacturing services, leveraging its advanced production facilities to produce pharmaceuticals for third parties. The company may also engage in partnerships and collaborations with other pharmaceutical firms to enhance its product offerings and market reach, contributing to its revenue streams.

IDT Australia Limited Financial Statement Overview

Summary

IDT Australia Limited is facing significant financial challenges, with consistent losses and negative cash flows. While there is some revenue growth, profitability and liquidity issues are prominent. The balance sheet shows increased leverage, which could pose risks if not managed carefully. Overall, the financial health of the company is weak, and strategic changes may be needed to improve performance.

Income Statement

IDT Australia Limited has shown some revenue growth, with a 5.28% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has also declined compared to previous years, suggesting challenges in cost management or pricing power.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but it remains relatively low compared to industry standards. The return on equity is negative, reflecting ongoing losses. However, the equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

IDT Australia Limited's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. This poses liquidity risks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.77M	19.77M	13.23M	6.93M	12.11M	15.99M
Gross Profit	9.69M	9.69M	10.42M	-3.53M	2.82M	4.88M
EBITDA	-6.54M	-6.54M	-5.56M	-8.83M	-340.00K	2.75M
Net Income	-8.06M	-8.06M	-5.41M	-8.50M	-1.16M	2.10M
Balance Sheet
Total Assets	36.92M	36.92M	31.37M	28.29M	30.08M	34.13M
Cash, Cash Equivalents and Short-Term Investments	4.11M	4.11M	904.00K	4.43M	9.21M	6.93M
Total Debt	10.40M	10.40M	4.47M	740.00K	881.00K	766.00K
Total Liabilities	15.03M	15.03M	7.93M	4.15M	3.46M	6.51M
Stockholders Equity	21.89M	21.89M	23.44M	24.14M	26.63M	27.61M
Cash Flow
Free Cash Flow	-7.55M	-7.55M	-10.30M	-8.42M	1.95M	-156.00K
Operating Cash Flow	-6.25M	-6.25M	-9.60M	-7.90M	2.86M	370.00K
Investing Cash Flow	-4.50M	-4.50M	-1.09M	-522.00K	-912.00K	-526.00K
Financing Cash Flow	10.75M	10.75M	6.77M	3.64M	337.00K	224.00K

IDT Australia Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.93 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	64 Neutral	AU$46.39M	12.96	7.64%	2.86%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	51 Neutral	AU$80.55M	715.00	0.19%	―	17.82%	―
NXS	47 Neutral	$43.89M	―	-289.70%	―	-4.27%	33.91%
IDT	41 Neutral	AU$24.40M	―	-35.58%	―	45.30%	-24.18%
AGH	41 Neutral	AU$19.03M	―	-218.38%	―	-47.30%	82.53%

IDT Australia Limited Corporate Events

IDT Australia Limited Announces Cessation of Securities

IDT Australia Limited announced the cessation of 861,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.